Sign in to view content

Patients Ultra-Responsive to Ranibizumab (RBZ): Rates of >4-Step Improvement in Diabetic Retinopathy Severity in DRCR.net Protocol S

Allen Chiang, MD, FASRS

Video
Published 2019

Related

Twelve Month Safety and Efficacy Outcomes from a Phase 2 Study of APL-2 in Patients with Geographic Atrophy
David S. Boyer, MD
Updates from the Field
2017
Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy The Phase II ALTITUDE Study
Dilsher S. Dhoot, MD
Annual Meeting Talks
2023
Defining a 'Strong' and 'Weak' Response to Anti-VEGF Treatment CI-DME: Retrospective Analysis of 3 DRCR Retina Network Clinical Trials
Sharon D. Solomon, MD
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more